In Vivo Models
Resources
Crispant is a new CRISPR/Cas9 method generates F0 mutant zebrafish that cuts costs, time, and reduces animal use for researchers interested in screening loss-of-function alleles in vivo. Using the F0 knockout method in zebrafish, it takes as little as a week to go from gene disruption to behavioral phenotype instead of more than six months using standard genetic approaches. The Crispant approach is an efficient tool for disease modeling, proof-of-concept studies, and lead target validation.
Using traditional CRISPR approaches to create a stable knockout model typically takes 9-12 months, making it incompatible with the fast pace of discovery of new genetic associations.
To combat the long lead times associated with traditional genetic models, InVivo Biosystems optimized the Crispant approach to create F0 knock-out animals by “breaking” a gene in multiple locations.
The transient knock-out line is generated in 1 month or less and can be used to directly create stable zebrafish knock-out mode
Crispant Verified Injection Mix: inject-ready mix containing 3 sgs and Cas9 enzyme.
Identify 5 sgs across the gene of interest, test in vivo cutting efficiency; select the verified 3 best cutters.
Crispant In Silico Predicted Injection Mix: inject-ready mix containing 3 sgs and Cas9 enzyme.
Identify 3 sgs across the gene of interest based on predicted cutting.
Replicating Heartstrings(tbx5a) mutant using crispant technique. Knock-out created in less than 1 month.
Fig. 1: See Crispant in action.
Fig. 2: Heartstrings Mutant (tbx5). Crispant phenocopies both the stable KO and the morphant showing (1) slowing of heartbeat, (2) long stretched out heart, and (3) partial or full loss of pectoral fins.
Ready to connect with us to learn more about working with our company or our technology?
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.
